SULFASALAZINE tablet

Valsts: Amerikas Savienotās Valstis

Valoda: angļu

Klimata pārmaiņas: NLM (National Library of Medicine)

Aktīvā sastāvdaļa:

SULFASALAZINE (UNII: 3XC8GUZ6CB) (SULFASALAZINE - UNII:3XC8GUZ6CB)

Pieejams no:

AvPAK

SNN (starptautisko nepatentēto nosaukumu):

SULFASALAZINE

Kompozīcija:

SULFASALAZINE 500 mg

Ievadīšanas:

ORAL

Receptes veids:

PRESCRIPTION DRUG

Ārstēšanas norādes:

Sulfasalazine tablets are indicated: - in the treatment of mild to moderate ulcerative colitis, and as adjunctive therapy in severe ulcerative colitis; and - for the prolongation of the remission period between acute attacks of ulcerative colitis. Sulfasalazine tablets are contraindicated in: Patients with intestinal or urinary obstruction, Patients with porphyria as sulfonamides have been reported to precipitate an acute attack, Patients hypersensitive to sulfasalazine, its metabolites, sulfonamides or salicylates. None reported.

Produktu pārskats:

Sulfasalazine Tablets, USP, 500 mg are round, mustard-colored, biconvex, imprinted " WATSON " and " 796 "on one side and partial bisect on the other side. They are available as follows: NDC 50268-730-15 (10 Tablets per card, 5 cards per carton) Dispensed in Unit Dose package. For Institutional Use Only. Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature].

Autorizācija statuss:

Abbreviated New Drug Application

Produkta apraksts

SULFASALAZINE- SULFASALAZINE TABLET
AVPAK
----------
SULFASALAZINE TABLETS, USP
RX ONLY
DESCRIPTION
Sulfasalazine Tablets, USP, 500 mg for oral administration.
THERAPEUTIC CLASSIFICATION: Anti-inflammatory agent.
CHEMICAL DESIGNATION: 5-([
_p_-(2-pyridylsulfamoyl)phenyl]azo)salicylic acid.
CHEMICAL STRUCTURE:
C
H
N
O
S
The molecular weight of sulfasalazine is 398.39.
INACTIVE INGREDIENTS: magnesium stearate, pregelatinized starch,
sodium starch
glycolate and stearic acid.
CLINICAL PHARMACOLOGY
PHARMACODYNAMICS
The mode of action of sulfasalazine (SSZ) or its metabolites,
5-aminosalicylic acid (5-
ASA) and sulfapyridine (SP), is still under investigation, but may be
related to the anti-
inflammatory and/or immunomodulatory properties that have been
observed in animal
and _in vitro _models, to its affinity for connective tissue, and/or
to the relatively high
concentration it reaches in serous fluids, the liver and intestinal
walls, as demonstrated
in autoradio-graphic studies in animals. In ulcerative colitis,
clinical studies utilizing rectal
administration of SSZ, SP, and 5-ASA have indicated that the major
therapeutic action
may reside in the 5-ASA moiety.
PHARMACOKINETICS
_In vivo _studies have indicated that the absolute bioavailability of
orally administered SSZ
is less than 15% for parent drug. In the intestine, SSZ is metabolized
by intestinal
bacteria to SP and 5-ASA. Of the two species, SP is relatively well
absorbed from the
intestine and highly metabolized, while 5-ASA is much less well
absorbed.
18
14
4
5
_Absorption:_
Following oral administration of 1 g of SSZ to 9 healthy males, less
than 15% of a dose
of SSZ is absorbed as parent drug. Detectable serum concentrations of
SSZ have been
found in healthy subjects within 90 minutes after the ingestion.
Maximum concentrations
of SSZ occur between 3 and 12 hours post-ingestion, with the mean peak
concentration
(6 mcg/mL) occurring at 6 hours.
In comparison, peak plasma levels of both SP and 5-ASA occur
approximately 10 hours
after dosing. This longer time